ChromaDex

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ChromaDex reports record revenue and eyes growth through partnerships

ChromaDex's strong revenue growth and positive EBITDA reflect operational improvements.
The company faces challenges in sales channels and marketing claims but sees growth opportunities.
Strategic focus on new partnerships, product development, and pharmaceutical initiatives for future growth.

ChromaDex reports robust Q1 performance, eyes innovation for growth

ChromaDex's Q1 2023 performance was strong, with notable growth in revenue and positive cash flows. The company faces challenges in recurring revenue conversion and aims for improved financial metrics. However, opportunities lie in innovation, R&D, and potential partnerships for future growth.

ChromaDex reports strong Q2 earnings and eyes market expansion

ChromaDex's Q2 performance reflects robust revenue growth, strong partnerships, and a commitment to scientific excellence, positioning the company for continued success.
While facing challenges such as customer retention and working capital management, ChromaDex remains focused on profitability and strategic investments for future growth.
Opportunities in expanding market share, leveraging key partnerships, and enhancing customer loyalty present avenues for sustained revenue growth and market leadership.
With a solid financial position and a balanced approach to growth, ChromaDex is poised to navigate challenges and capitalize on opportunities in the evolving market landscape.

ChromaDex reports robust Q3 results, eyes growth through strategic partnerships

ChromaDex's Q3 performance reflects revenue growth, profitability, and operational efficiency, supported by strong financials and strategic partnerships.
The company's focus on innovation, market expansion, and cost control measures positions it well for sustained growth and competitive advantage.
While facing challenges in a dynamic market environment, ChromaDex's opportunities lie in product innovation, market diversification, and strategic partnerships.
Overall, ChromaDex's strategic initiatives and financial strength indicate a positive outlook for future growth and market expansion.

ChromaDex reports robust earnings, eyes growth through partnerships and innovation

ChromaDex delivered strong financial performance in Q4 2023 and full year 2023, driven by revenue growth, partnerships, and product demand.
While facing challenges in meeting consumer demand and optimizing resource allocation, the company remains focused on responsible practices and future growth opportunities.
With a solid financial foundation, strategic partnerships, and a focus on innovation, ChromaDex is poised for continued growth and market leadership in the dietary supplement industry.

ChromaDex reports revenue growth and strategic partnerships for future expansion

ChromaDex's Q1 2024 performance reflects revenue growth, positive EBITDA, and strategic initiatives for future expansion.
The company's strengths lie in subscriber base building, successful product SKUs, and stable market presence in key segments.
While facing challenges such as increased expenses and short-term R&D investments, ChromaDex is well-positioned for growth.
Opportunities in new partnerships, product development, and market exploration offer avenues for revenue growth and enhanced customer value.

ChromaDex reports revenue growth and product innovation in Q2

ChromaDex's Q2 2024 performance showed revenue growth, positive EBITDA, and a strong cash position.
The company's strengths lie in its innovative NIAGEN product line and positive clinical study outcomes.
Challenges include market misinformation and the need to adjust outlook due to product delays.
Opportunities exist in addressing specific health conditions and leveraging marketing strategies for growth.

ChromaDex (CDXC) reports record Q3 results and eyes growth

ChromaDex (CDXC) delivers strong Q3 performance with record revenue and profitability, driven by e-commerce and product launches.
Despite challenges in outlook adjustment and pricing strategies, the company's financial discipline and market focus position it for growth.
Opportunities lie in expanding product reach, FDA approvals, and strategic marketing to capitalize on market potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2021. Second Quarter 2021 and Recent Highlights Total net sales were $17.7 million, up 16% from the prior year quarter. Tru Niagen® net sales were $15.4 million, a 31% increase from the prior year quarter. Gross margin was 61.1%, a 170 basis point increase from the prior year quarter. Net loss was $(5.6) million or $(0.08) per share, down $0.02 per share from the prior year qu

ChromaDex Corporation Reports Second Quarter 2021 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the second quarter results

ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

ChromaDex Corp. (NASDAQ: CDXC) participated in a virtual presentation at the Benzinga Small Cap Conference in May 2021. ChromaDex CEO Rob Fried also presented on a panel discussing "Investing in Longevity Science: The New Drugs & Therapies Designed to Prolong Your Lifespan.

CHROMADEX'S HEALTHY AGING PRODUCTS GAIN NEW TRACTION WITH FOUR HUGE DISTRIBUTION AGREEMENTS INCLUDING WALMART

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of four recently published preclinical studies, highlighting new findings for its patented nicotinamide riboside (NR) healthy aging nutrient. Through the industry-leading ChromaDex External Research Program (CERP™), ChromaDex provides its patented NR ingredient, Niagen®, technological and scientific expertise to research institutions and universities at no cost. ChromaDex continues to support NAD+ research t

ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP™)

The company's flagship product was launched in Walmart stores across the U.S.

Why ChromaDex Stock Is Jumping Today

ChromaDex Corp (NASDAQ: CDXC) has launched its flagship consumer product Tru Niagen in Walmart Inc (NYSE: WMT), available in 3,800 stores across the U.S. The NAD+ booster will be offered to Walmart customers in two distinct serving sizes, 100mg and 300mg.

ChromaDex Shares Jump on Tru Niagen's Launch In Walmart Stores

The stock price of Chromadex Corp (NASDAQ: CDXC) increased by over 10% pre-market. This is why it happened.

CDXC Stock Price: Over 10% Increase Pre-Market Explanation

The stock price of Chromadex Corp (NASDAQ: CDXC) increased by over 14% pre-market. This is why it happened.

CDXC Stock Price: Over 14% Increase Pre-Market Explanation

Shares of ChromaDex Corp. shot up 12.8% in premarket trading Monday, after the maker of healthy aging supplements said its Tru Niagen will become available in 3,800 Walmart Inc. stores in the U.S. ChromaDex said Tru Niagen is a form of vitamin B3 that helps elevate NAD+, to reduce the impact of aging and daily wear and tear on the body. "We are grateful to Walmart for their commitment to the Tru Niagen® brand and for their collaboration in planning this launch," said Chief Executive Rob Fried.

ChromaDex stock jumps after its Tru Niagen to become available at Walmart

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of its flagship consumer product Tru Niagen® in Walmart, available in 3,800 stores across the United States. Walmart is the first major U.S. retailer to bring this well-studied healthy aging nutrient to stores. “We are grateful to Walmart for their commitment to the Tru Niagen® brand and for their collaboration in planning this launch,” says ChromaDex CEO Rob Fried. “We are excited to make our product availab

ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States

ChromaDex (CDXC) CEO Robert Fried on Q1 2021 Results - Earnings Call Transcript

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2021 financial results. First Quarter 2021 and Recent Highlights Total net sales of $14.7 million, up 2% from $14.3 million in the year ago quarter. Tru Niagen® net sales of $12.4 million, a 12% increase from the year ago quarter. Gross margin of 62.9%, a 500 basis point increase from the year ago quarter. Net loss was ($7.4) million or ($0.12) per share, down $0.02 per share year-over-year. Adjusted EBITDA

ChromaDex Corporation Reports First Quarter 2021 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology company. The agreement provides Ro with rights to ChromaDex's patented nicotinamide riboside ingredient Niagen®, the sole active ingredient in Tru Niagen®, for specially formulated Roman products. “Ro has made great strides in a short period of time and we are looking forward to working with them to improve the well-being of t

ChromaDex and Ro Partner for New Product Development

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 6, 2021 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the first quarter results and

ChromaDex to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a strategic supply agreement with Health & Happiness (H&H) Group, a global leader in premium health, human and pet nutrition and personal care brands. The agreement provides H&H Group with rights to ChromaDex's patented nicotinamide riboside ingredient Niagen®, the sole active ingredient in Tru Niagen®, for exclusively formulated Swisse® products. Tru Niagen® is an industry-leading, award-win

ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen®

Last week I was fortunate to meet Rob Fried, CEO of ChromaDex, in my podcast for a very interesting talk about his promising company. With its dietary supplement Tru Niagen, ChromaDex is at the forefront of the battle against aging. Tru Niagen is proven to safely elevate NAD, which has several age-related health benefits.

ChromaDex Growth Story Just Getting Started: Interview With CEO Rob Fried

ChromaDex develops and sells an anti-aging drug called Tru Niagen.

ChromaDex: An Anti-Aging Company With Major New Deals

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #management--ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Fadi Karam as Chief Marketing Officer. Karam has spent his career driving consumer businesses across multiple geographies and cultures, including scaling direct-to-consumer operations across digital, social, and traditional marketing platforms, as well as launching and scaling product innovation. Prior to joining ChromaDex, Karam led the local brand portfolio for Nestlé Waters North America with ov

ChromaDex Appoints Fadi Karam as Chief Marketing Officer

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen® nicotinamide riboside (NR) and citrin deficiency, a rare genetic condition. In collaboration with the ChromaDex External Research Program (CERP™) and leading research institutions, the Citrin Foundation will fund a series of preclinical and clinical studies to explore the potential impact of increased NAD+ levels on patien

ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Lytham Partners Spring 2021 Investor Conference. The ChromaDex management team is scheduled to present on Wednesday, March 31, 2021 at 10:15 a.m. Eastern Time (7:15 a.m. Pacific Time). The presentation will be webcast live via the link below on the investor relations section of the Company's website

ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference

Investors need to pay close attention to ChromaDex (CDXC) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in ChromaDex (CDXC) Stock?

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Zooming with LD investor conference. The ChromaDex management team is scheduled to present on Thursday, March 25, 2021 at 12:30 p.m. Eastern Time (9:30 a.m. Pacific Time). The presentation will be webcast live via the link below on the investor relations section of the Company's website at www.chroma

ChromaDex to Present at the Zooming with LD Virtual Investor Conference

Another investment bank lifts its price target on the company's stock.

Why ChromaDex Trounced the Market on Tuesday

ChromaDex's (CDXC) CEO Rob Fried on Q4 2020 Results - Earnings Call Transcript

ChromaDex (CDXC) delivered earnings and revenue surprises of 9.09% and 0.31%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

News for ChromaDex Stock (CDXC)